Cardiff Oncology (CRDF) to Release Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) will likely be announcing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $0.0890 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Tuesday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%. On average, analysts expect Cardiff Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cardiff Oncology Trading Up 4.3%

Shares of Cardiff Oncology stock opened at $1.68 on Thursday. The stock has a market capitalization of $114.86 million, a price-to-earnings ratio of -2.43 and a beta of 1.36. Cardiff Oncology has a twelve month low of $1.48 and a twelve month high of $4.56. The business’s 50 day simple moving average is $1.75 and its 200-day simple moving average is $2.11.

Hedge Funds Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Franklin Resources Inc. bought a new stake in Cardiff Oncology during the 4th quarter valued at $3,388,000. Laurion Capital Management LP boosted its position in Cardiff Oncology by 37.2% during the 3rd quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock worth $5,080,000 after acquiring an additional 668,590 shares during the period. Acorn Capital Advisors LLC grew its stake in shares of Cardiff Oncology by 39.3% in the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock worth $4,042,000 after purchasing an additional 553,317 shares in the last quarter. Millennium Management LLC grew its stake in shares of Cardiff Oncology by 441.5% in the fourth quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock worth $546,000 after purchasing an additional 158,519 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Cardiff Oncology by 7.5% during the second quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after purchasing an additional 104,409 shares during the period. 16.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Piper Sandler cut their target price on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen raised shares of Cardiff Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.10.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.